These results suggest that differences in HR+ (ER−/PR+ vs. ER+/PR− or ER+/PR+) tumor biology are likely to be clinically significant and play a role in breast cancer disease, regardless of HER2 status. This evidence concerns the gene ERBB2 and breast cancer.